{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:22:49Z","timestamp":1792106569599,"version":"4.4.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The use of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) is mainly based on robust, pivotal clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To provide data on clinical use of BIC\/FTC\/TAF in real life.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>This was an observational, retrospective and single-centre study. We included all adult, treatment-naive (TN) and treatment-experienced (TE) people living with HIV (PLWH) starting BIC\/FTC\/TAF from 8 June 2018. We evaluated effectiveness [on treatment (OT), modified intention-to-treat (mITT) and intention-to-treat (ITT)], tolerability and safety in those patients who reached 6 months of follow-up (M6).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 1584 PLWH [213 TN (13%) and 1371 TE (87%)]. The median (IQR) follow-up was 16 (7\u201321) months, with 81% and 53% of PLWH reaching M6 and M12, respectively. By OT, mITT and ITT, HIV-RNA &amp;lt;50 copies\/mL was 77%, 70% and 62% at M6 and 92%, 77% and 63% at M12 for TN PLWH and 94%, 89% and 83% at M6 and 93%, 85% and 78% at M12 for TE PLWH, respectively. In PLWH carrying an M184V\/I substitution, OT RNA &amp;lt;50 copies\/mL was 89.5% at M6. The median CD4 cell count increased from 329 to 511\/\u03bcL in TN PLWH and from 630 to 683\/\u03bcL in TE PLWH at M6. Of the total, 1148 (88%) PLWH continued on BIC\/FTC\/TAF at M6. The most frequent known reason for discontinuation was toxicity [42 (69%) cases]; only 7 cases were considered virological failures (0.6% of the total OT cohort at M6), with no emerging resistance substitutions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In real life, BIC\/FTC\/TAF showed high rates of virological suppression and also in PLWH carrying lamivudine\/emtricitabine resistance substitutions. The tolerability and safety of BIC\/FTC\/TAF were good, with high persistence observed for patients on this regimen at M6.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab481","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T20:12:59Z","timestamp":1639426379000},"page":"1133-1139","source":"Crossref","is-referenced-by-count":74,"title":["Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre"],"prefix":"10.1093","volume":"77","author":[{"given":"Juan","family":"Ambrosioni","sequence":"first","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhon","family":"Rojas Li\u00e9vano","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Berrocal","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"de la Mora","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez-Cord\u00f3n","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Mart\u00ednez-Rebollar","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Torres","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainoa","family":"Ugarte","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Chivite","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Leal","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Lazzari","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Mir\u00f3","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Blanco","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"2022033111241718300_dkab481-B1","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"key":"2022033111241718300_dkab481-B2","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2022033111241718300_dkab481-B3","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2022033111241718300_dkab481-B4","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2022033111241718300_dkab481-B5","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","article-title":"Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"2022033111241718300_dkab481-B6","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022033111241718300_dkab481-B7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1473-3099(12)70134-2","article-title":"Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement","volume":"12","author":"Crawford","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2022033111241718300_dkab481-B8","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2022033111241718300_dkab481-B9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/hiv.12878","article-title":"2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0","volume":"21","author":"Ryom","year":"2020","journal-title":"HIV Med"},{"key":"2022033111241718300_dkab481-B10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/QAI.0000000000002454","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) from dolutegravir (DTG) + F\/TAF or DTG + F\/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance","volume":"85","author":"Acosta","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022033111241718300_dkab481-B11","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022033111241718300_dkab481-B12","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40121-021-00449-z","article-title":"Meta-analysis of efficacy and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide among people living with HIV","volume":"10","author":"Chen","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2022033111241718300_dkab481-B13","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/S2352-3018(19)30404-7","article-title":"Antiretroviral resistance and management after pre-exposure to prophylaxis","volume":"7","author":"Tittle","year":"2020","journal-title":"Lancet HIV"},{"key":"2022033111241718300_dkab481-B14","doi-asserted-by":"crossref","first-page":"180080","DOI":"10.1183\/16000617.0080-2018","article-title":"Randomised controlled trials and real-life studies: two answers for one question","volume":"27","author":"Harari","year":"2018","journal-title":"Eur Respir Rev"},{"key":"2022033111241718300_dkab481-B15","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2352-3018(20)30271-X","article-title":"Primary HIV-1 infection in users of pre-exposure prophylaxis","volume":"8","author":"Ambrosioni","year":"2021","journal-title":"Lancet HIV"},{"key":"2022033111241718300_dkab481-B16","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/S2352-3018(21)00070-9","article-title":"Overview of SARS-CoV-2 infection in adults living with HIV","volume":"8","author":"Ambrosioni","year":"2021","journal-title":"Lancet HIV"},{"key":"2022033111241718300_dkab481-B17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/14787210.2014.913981","article-title":"Update on antiretroviral treatment during primary HIV infection","volume":"12","author":"Ambrosioni","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2022033111241718300_dkab481-B18","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cmi.2018.10.021","article-title":"Epidemiological changes of acute\/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997\u20132015): a prospective cohort study","volume":"25","author":"Nicol\u00e1s","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2022033111241718300_dkab481-B19","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/jac\/dkaa349","article-title":"Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping","volume":"75","author":"Casadell\u00e0","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022033111241718300_dkab481-B20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jac\/dkw376","article-title":"Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute\/recent HIV infection","volume":"72","author":"Ambrosioni","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022033111241718300_dkab481-B21","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/QAD.0000000000002243","article-title":"E157Q integrase strand-transfer inhibitor substitution in patients with acute\/recent HIV infection","volume":"33","author":"Ambrosioni","year":"2019","journal-title":"AIDS"},{"key":"2022033111241718300_dkab481-B22","doi-asserted-by":"crossref","first-page":"e0125837","DOI":"10.1371\/journal.pone.0125837","article-title":"Trends in transmission of drug resistance and prevalence of non-B subtypes in patients with acute or recent HIV-1 infection in Barcelona in the last 16 years (1997\u20132012)","volume":"10","author":"Ambrosioni","year":"2015","journal-title":"PLoS One"},{"key":"2022033111241718300_dkab481-B23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"2022033111241718300_dkab481-B24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2022033111241718300_dkab481-B25","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022033111241718300_dkab481-B26","doi-asserted-by":"crossref","first-page":"102779","DOI":"10.1016\/j.ebiom.2020.102779","article-title":"Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)","volume":"55","author":"De Miguel","year":"2020","journal-title":"EBioMedicine"},{"key":"2022033111241718300_dkab481-B27","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/jac\/dkaa505","article-title":"Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity","volume":"76","author":"Livio","year":"2021","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/4\/1133\/43192415\/dkab481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/4\/1133\/43192415\/dkab481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:01:33Z","timestamp":1648735293000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/4\/1133\/6510932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,1,19]]},"published-print":{"date-parts":[[2022,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab481","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,1,19]]}}}